Millennium holds 4.9% stake in Capricor

Capricor Therapeutics, Inc. (CAPR) is the subject of a Schedule 13G reporting the equity position of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander in Capricor’s common stock.

Rhea-AI Filing Summary

Capricor Therapeutics, Inc. (CAPR) is the subject of a Schedule 13G reporting the equity position of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander in Capricor’s common stock. The reporting persons disclose beneficial ownership of 2,857,387 Capricor shares, representing 4.9% of the outstanding common stock, with no sole voting or dispositive power and full holdings under shared voting and shared dispositive power.

The group states that it acquired more than 5% of Capricor’s outstanding common stock on August 17, 2026, but by the date of this report its beneficial ownership had fallen to 5% or less. The filing explains that the securities are held by entities over which Millennium-related managers have voting control and investment discretion, and it disclaims that this structure alone constitutes an admission of beneficial ownership.

Key Figures

Shares beneficially owned: 2,857,387 shares Percent of class: 4.9% Sole voting power: 0 shares +4 more

7 metrics

Shares beneficially owned 2,857,387 shares Capricor common stock reported as beneficially owned by the group

Percent of class 4.9% Percentage of Capricor common stock class beneficially owned

Sole voting power 0 shares Capricor shares over which the group has sole voting power

Shared voting power 2,857,387 shares Capricor shares over which the group has shared voting power

Sole dispositive power 0 shares Capricor shares over which the group has sole dispositive power

Shared dispositive power 2,857,387 shares Capricor shares over which the group has shared dispositive power

Date exceeded 5% ownership August 17, 2026 Date on which beneficial ownership first rose above 5% of the class

Key Terms

beneficial ownership, shared voting power, dispositive power, Schedule 13G

4 terms

beneficial ownership financial

"After acquiring beneficial ownership of more than 5% of the outstanding Common Stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power financial

"Shared Voting Power 2,857,387.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power financial

"Shared Dispositive Power 2,857,387.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Capricor Therapeutics, Inc. is the subject of a Schedule 13G reporting"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Capricor Therapeutics (CAPR) does Millennium currently report owning?

Millennium and related reporting persons disclose beneficial ownership of 4.9% of Capricor Therapeutics’ common stock. This equals 2,857,387 shares, all reported under shared voting and shared dispositive power, with no sole voting or sole dispositive authority indicated in the Schedule 13G.

How many Capricor (CAPR) shares are reported as beneficially owned by Millennium?

The reporting group lists beneficial ownership of 2,857,387 shares of Capricor common stock. These shares are attributed to entities over which Millennium-related managers have voting control and investment discretion, and are reported entirely as shared voting and shared dispositive power positions.

Did Millennium’s beneficial ownership in Capricor (CAPR) exceed 5% at any point?

The filing states the reporting persons acquired more than 5% of Capricor’s outstanding common stock on August 17, 2026. By the date of the Schedule 13G, their beneficial ownership had decreased, so they reported holding 5% or less of the class.

What voting power does Millennium report over its Capricor (CAPR) shares?

The Schedule 13G shows 0 shares with sole voting power and 2,857,387 shares with shared voting power. Sole dispositive power is also 0 shares, while all 2,857,387 shares are reported with shared dispositive power across the reporting entities.

Who are the reporting persons in this Capricor (CAPR) Schedule 13G filing?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. The filing explains that securities are held by entities under their voting control or investment discretion, while expressly stating this does not itself admit beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 07:07 PM Accepted by SEC EDGAR 08/19/2026 - 07:07 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Capricor Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

14070B309

(CUSIP Number)

08/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 14070B309

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,857,387.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,857,387.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,857,387.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 14070B309

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,857,387.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,857,387.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,857,387.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 14070B309

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,857,387.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,857,387.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,857,387.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Capricor Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 10865 Road to the Cure, Suite 150, San Diego, California 92121
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 14070B309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page. After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on August 17, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	08/18/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	08/18/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	08/18/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of August 18, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.